Research · Interpretation · ContextNovember 16, 2026
The Testosterone Review

Hormone health, beyond the hype

Testosterone / EVIDENCE GUIDE

Low testosterone and anemia: when hormone treatment raises hemoglobin

Randomized trials show testosterone can correct anemia in selected hypogonadal men, but anemia still needs a cause-focused evaluation and blood-count monitoring.

Human red blood cells under phase-contrast microscopy.
Human red blood cells under phase-contrast microscopy. · Tatyana Tisho · CC BY-SA 3.0 · Source · License
THE KEY TAKEAWAY

Testosterone treatment can raise hemoglobin and correct anemia in some men with confirmed hypogonadism, but it is not a general anemia treatment and can overshoot into erythrocytosis.

Testosterone influences red-blood-cell production

Androgens stimulate erythropoiesis through erythropoietin, iron regulation, and other marrow effects. Men with severe or persistent testosterone deficiency can develop mild normocytic anemia. This relationship makes unexplained anemia a potentially relevant sign during a broader hypogonadism evaluation.

It does not mean low testosterone is the first or most likely cause of every low hemoglobin. Blood loss, iron or vitamin deficiency, kidney disease, inflammation, marrow disorders, medications, and gastrointestinal disease can be more urgent. The anemia workup should not stop when one low hormone value appears.

A complete blood-count analyzer.
A complete blood-count analyzer. · Jakednb · CC BY-SA 4.0 · Source · License

The Testosterone Trials showed a hemoglobin response

A placebo-controlled trial enrolled men age 65 or older with unequivocally low testosterone. Among those with unexplained anemia, 54% receiving testosterone had hemoglobin rise by at least 1.0 g/dL at 12 months, compared with 15% receiving placebo. More treated men were no longer anemic.

Benefits also appeared among participants whose anemia had another known cause. However, the trial was not proof that testosterone replaces iron, vitamin B12, kidney treatment, or evaluation for bleeding. It tested selected older men with low testosterone, not all patients with anemia.

A larger trial reinforced the signal

The 2023 TRAVERSE anemia study evaluated middle-aged and older men with hypogonadism in a much larger randomized population. Testosterone corrected anemia more often than placebo and reduced the development of new anemia among men who were not anemic at baseline.

Large randomized evidence makes the hemoglobin effect more credible, but clinical value depends on symptoms, cause, and safety. Correcting a laboratory threshold is most meaningful when fatigue, function, or another patient-centered outcome improves and when a dangerous anemia cause has not been missed.

The same pathway can overshoot

Some nonanemic participants in the earlier trial developed hemoglobin above 17.5 g/dL. Testosterone increases the risk of erythrocytosis, so a blood count is both an efficacy measure in anemia and a safety measure during treatment.

Baseline hematocrit should be checked, followed by repeat testing after treatment begins and periodically thereafter. If hematocrit rises excessively, dose reduction, a formulation change, treatment interruption, or evaluation for sleep apnea, smoking-related hypoxia, or a blood disorder may be needed.

A hematocrit separator.
A hematocrit separator. · Marek M ( talk ) 23:07, 16 April 2011 (UTC) · CC BY-SA 3.0 · Source · License

Who might need testosterone testing?

An older man with unexplained anemia plus reduced libido, fewer spontaneous erections, hot flashes, infertility, low bone density, or other compatible signs may reasonably discuss morning testosterone testing. Diagnosis requires consistent low values, not an anemia result plus a single borderline hormone test.

Luteinizing and follicle-stimulating hormones help identify whether the problem is testicular or central. Medication review matters because opioids, glucocorticoids, cancer treatment, and prior anabolic steroids can influence the axis. Anemia and low testosterone may also share an underlying chronic illness.

Keep the treatment claim narrow

For a man with confirmed hypogonadism and anemia, a hemoglobin rise can be a legitimate expected effect. For a person with normal testosterone, using testosterone as an energy or blood-building drug is unsupported and introduces fertility, prostate, cardiovascular, and erythrocytosis concerns.

Track hemoglobin, hematocrit, the identified anemia cause, and the symptom target. The evidence is encouraging in a defined population, but the responsible message is not “testosterone cures anemia.” It is that androgen deficiency belongs on the differential diagnosis when the clinical picture supports it.

Anemia severity determines urgency

Mild stable anemia discovered on routine testing is different from a rapid hemoglobin fall, black or bloody stool, chest pain, shortness of breath at rest, fainting, or marked weakness. Acute or symptomatic anemia needs prompt evaluation for bleeding or another serious cause, not a delayed testosterone workup.

Even when testosterone deficiency contributes, clinicians may still need iron studies, reticulocyte count, kidney function, vitamin levels, inflammatory markers, or gastrointestinal evaluation. More than one cause can coexist. Improvement after testosterone does not retroactively prove that no other diagnosis was present.

A cause-focused evaluation remains necessary even when hormone treatment is being considered, because correcting the blood count and explaining the anemia are separate clinical goals.

Sources & further reading

  1. Association of Testosterone Levels With Anemia in Older Men: controlled clinical trial ↗
  2. Efficacy of Testosterone Replacement Therapy in Correcting Anemia in Men With Hypogonadism ↗
  3. Testosterone Therapy in Men With Hypogonadism: Endocrine Society guideline ↗

This article provides educational information. Ask a qualified clinician or pharmacist about your symptoms, medical conditions, medicines and supplement interactions.

More on Testosterone →